Key Highlights
- Glucotrack shares fell 29.46% to $1.82 at last closing, giving back most of a sharp rally from the prior session after a discounted stock offering was priced.
- The company sold 169,388 common shares and 1,350,220 pre-funded warrants at roughly $2.04 each, priced well below the prior day's closing level.
- The offering, together with the warrants, covers about 1.52 million shares, nearly tripling the roughly 798,144 shares outstanding after an August reverse split.
- Proceeds are earmarked first to pay off existing debt, with the company keeping about $2.85 million after an 8% Placement fee.
Glucotrack, Inc. (NASDAQ:GCTK) Penny Stock fell sharply after announcing it had priced a registered direct offering worth about $3.1 million in gross proceeds, a day after shares had jumped strongly on news about the company's Lōkahi Therapeutics business. The offering priced well below the prior close, a signal that investors buying the new stock were only willing to pay a much lower price than the market had just set, and Friday's trading moved toward that lower level.
The deal consists of 169,388 common shares at $2.04 each and 1,350,220 pre-funded warrants at $2.039 each, sold to unnamed institutional investors with Dawson James Securities acting as sole placement agent for an 8% fee. A pre-funded Warrant is essentially a share bought almost in full upfront, with the holder paying a tiny remaining exercise price to convert it into stock, often used by investors to avoid crossing ownership limits.
Latest Developments
The new shares and pre-funded warrants together cover about 1.52 million shares. When Glucotrack carried out a 1-for-15 reverse split effective August 31, it said about 798,144 shares would be outstanding afterward, meaning the offering would nearly triple the share count on that basis, a large amount of dilution for existing holders. The company agreed to a 90-day lock-up for directors and executive officers and committed not to issue new stock or enter variable-rate financing for six months after closing.
The comparison to Glucotrack's other recent financing may unsettle holders: on September 11, the company announced a convertible note financing of about $11.5 million in principal, with an initial conversion price of $3.12 per share and warrants exercisable at $7.50. The new registered direct offering is priced below that conversion level, only two weeks later.
Financial and Business Position
Glucotrack began as a developer of diabetes technology, with its main product candidate a long-term implantable continuous blood glucose monitor still limited to investigational use. In July 2026 the company completed a business combination with Lōkahi Therapeutics, a privately held biopharmaceutical platform, under which Lōkahi became the controlling entity and its shareholders received roughly 90% of the combined company on a fully diluted basis, while Glucotrack's Nasdaq listing was retained.
Lōkahi describes itself as a capital-efficient platform that finds, acquires and advances overlooked therapeutic assets. Its lead program, LT-100, is a bee-venom-derived treatment being developed with Apimeds Pharmaceuticals for knee osteoarthritis pain, and the company said in August it had started clinical trial Manufacturing for the program. The company said the offering proceeds will first pay off existing debt, with anything left going to working capital, though it did not identify which Debt will be repaid.
Stock-Market Context
The company remains under listing pressure, having disclosed in August that it must keep a closing bid of at least $1.00 through November 9, 2026, under oversight by a Nasdaq Hearings Panel, warning that failing to do so could lead to delisting. Selling stock into a spike is a common move for small, cash-hungry companies, and the after-the-bell timing turned a momentum trade for Thursday's buyers into a dilution story overnight.
Dilution Weighed Against a Compliance Deadline
Investors are watching for a filing confirming the offering closed and showing net proceeds after fees, which debt is being paid off and whether the September convertible notes are affected, how quickly the 1.35 million pre-funded warrants convert into shares, and the November 9 Nasdaq compliance deadline as the share price trend remains under panel oversight.






Please wait processing your request...